Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
AssigneeHospital for Joint Diseases
InventorsAshok Amin, Steven Abramson, Inoravadan V. Patel
Life of this patent
Estimating the term…
Abstract
Chemically modified tetracyclines are a new class of non-steroidal anti-inflammatory drugs which inhibit cyclooxygenase-2 and tumor necrosis factor alpha. These chemically modified tetracyclines are used in a method for inhibiting COX-2, which in turn inhibits PGE2, and/or inhibiting TNFα. They are also used in a method for treating a disease or disorder associated with elevated activities of COX-2 (i.e., increased production of PGE2) and/or TNFα.
Claims2
A method for treating a disease or disorder associated with an elevated level of TNFα and/or products of COX-2 activity, comprising administering to a subject in need thereof a chemically modified tetracycline compound having negligible anti-microbial activity in an amount sufficient to reduce the expression or activity of COX-2 and/or TNFα in the subject to treat a disease or disorder associated with an elevated level of TNFα and/or products of COX-2 activity selected from the group consisting of multiple sclerosis, septic shock, graft-vs.-host disease, cerebral malaria, cachexia associated with HIV infection, brain ischemia, inflammatory bowel disease, and neurodegenerative disorders.
Dependencies are inferred from the claim text.